智通财经APP讯,科笛-B(02487)发布公告,配售已于2025年9月5日根据配售协议的条款及条件完成。配售代理已成功配售合共2890.4万股配售股份予TruMed Health Innovation Fund LP、Octagon Investments Master Fund LP及Octagon Private Opportunities Fund II LP,配售价为每股股份8.40港元。配售所得款项总额约为2.43亿港元。配售所得款项净额约为2.4亿港元。
智通财经APP讯,科笛-B(02487)发布公告,配售已于2025年9月5日根据配售协议的条款及条件完成。配售代理已成功配售合共2890.4万股配售股份予TruMed Health Innovation Fund LP、Octagon Investments Master Fund LP及Octagon Private Opportunities Fund II LP,配售价为每股股份8.40港元。配售所得款项总额约为2.43亿港元。配售所得款项净额约为2.4亿港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.